Category: Biography

Orcid

Sutability For Best Researcher Award – Dr. Milo Frattini

Dr. Milo Frattini is an exceptionally strong candidate for the Best Researcher Award based on his extensive contributions to molecular oncology, translational cancer research, and diagnostic innovation. With over 20 years of impactful research, he has established himself as a scientific leader in integrating molecular diagnostics into routine cancer care. His sustained publication record (100+ peer-reviewed papers), leadership in clinical laboratory management, editorial contributions, and collaborative role in national cancer groups position him as a cornerstone of precision oncology in Switzerland and beyond.

🎓 Education

Dr. Milo Frattini’s academic foundation began at the Scientific Lyceum of Milan, where he received a strong grounding in science. He pursued his undergraduate degree in Biology at the Università degli Studi of Milan, graduating in 1998 with the highest distinction (110/110 cum laude). His thesis investigated calcium-dependent protein kinases in rice, reflecting his early interest in molecular biology. Building upon this foundation, Dr. Frattini later transitioned his focus toward human health and cancer research. In 2014, he earned a Ph.D. in Experimental Medicine and Oncology from the University of Insubria in Varese, Italy. His doctoral thesis explored the molecular characteristics of small bowel adenocarcinoma, aiming to identify novel therapeutic targets. His educational trajectory demonstrates a unique evolution from plant molecular biology to clinical oncology, establishing the multidisciplinary expertise that underpins his current contributions to molecular pathology and precision oncology.

🧪 Experience

Dr. Frattini’s professional journey began in 1999 as a Research Fellow at the Consiglio Nazionale delle Ricerche in Milan, where he studied calcium-dependent protein kinases. From 2000 to 2005, he expanded his expertise in cancer biology as a Research Fellow at the Istituto Nazionale dei Tumori in Milan, focusing on experimental molecular pathology. Since 2005, he has been leading the Laboratory of Molecular Pathology at the Institute of Pathology in Locarno, Switzerland. In this role, he oversees advanced molecular diagnostic workflows, contributing directly to clinical decision-making. Since 2008, he has also managed the institute’s quality control systems, ensuring diagnostic accuracy and compliance with international standards. With extensive laboratory leadership and hands-on clinical experience, Dr. Frattini plays a key role in integrating molecular diagnostics into routine cancer care. His dual expertise in laboratory science and clinical pathology places him at the forefront of translational oncology research in Switzerland.

📈 Professional Development

Dr. Frattini has actively pursued professional development through editorial leadership, society memberships, and quality assurance roles. From 2010 to 2016, he served as Associate Editor of BMC Cancer, a prominent oncology journal. Since 2021, he has continued his editorial service with the Journal of Clinical Medicine, helping to guide scientific discourse in clinical research. He is a dedicated member of the Swiss Society of Pathology and the Swiss Group for Molecular Pathology, contributing to national standards in molecular diagnostics. Additionally, he participates in the SAKK Gastrointestinal and Lung Cancer Groups, which are instrumental in shaping Swiss clinical cancer trials. Dr. Frattini also holds the role of Head of Quality Control at his institute, ensuring laboratory processes meet stringent clinical and regulatory criteria. These roles demonstrate his commitment not only to research excellence but also to the development of best practices in molecular pathology, professional collaboration, and clinical innovation.

🔬 Research Focus

Dr. Frattini’s research focuses on the molecular characterization of solid tumors, with a particular emphasis on gastrointestinal and pulmonary cancers. His work aims to uncover the genomic and epigenetic alterations that drive tumor progression and treatment resistance. By integrating molecular profiling into diagnostic workflows, his research supports the personalization of cancer therapy. His Ph.D. work on small bowel adenocarcinoma—a rare and under-researched cancer—demonstrates his commitment to uncovering novel targets in hard-to-treat malignancies. He is also involved in studying molecular markers that predict patient response to targeted therapies and immunotherapies. Through collaborations with the SAKK groups, he contributes to clinical trial development and biomarker validation in real-world oncology settings. His translational research serves as a bridge between laboratory discoveries and bedside applications, significantly enhancing diagnostic precision and treatment outcomes in cancer care.

🧠 Research Skills

Dr. Frattini possesses a comprehensive skill set that spans molecular diagnostics, biomarker discovery, next-generation sequencing (NGS), and translational oncology. He is proficient in applying molecular biology techniques—such as PCR, DNA sequencing, and FISH—to clinical pathology. His leadership of a molecular pathology laboratory involves the integration of high-throughput genomic analysis with traditional histopathology, optimizing tumor profiling for patient-specific treatments. He has experience in validating diagnostic assays for clinical use, ensuring both analytical sensitivity and specificity. His research also includes skillful design and interpretation of retrospective and prospective molecular studies, which inform therapeutic decisions in gastrointestinal and lung cancers. Additionally, his editorial and review work reflect advanced skills in scientific evaluation, literature synthesis, and methodological rigor. Dr. Frattini’s ability to combine technical expertise, clinical understanding, and quality control makes him an asset to the fields of precision medicine and oncology diagnostics.

🏆 Awards and Honors

While specific named awards are not listed in the CV, Dr. Milo Frattini’s career reflects numerous professional honors and responsibilities that underline his recognition in the scientific community. His long-standing editorial roles with BMC Cancer and Journal of Clinical Medicine indicate a high level of peer respect and scientific credibility. Being appointed as Head of both the Molecular Pathology Laboratory and Quality Control Division at the Institute of Pathology in Locarno is a significant institutional acknowledgment of his leadership and expertise. Furthermore, his membership in elite professional bodies such as the Swiss Group for Molecular Pathology, the Swiss Society of Pathology, and SAKK oncology groups points to his continued professional trust and influence. These roles, though not formal awards, collectively highlight Dr. Frattini’s impact, reliability, and sustained excellence in cancer research and molecular diagnostics.

Publication Top Notes

1. Neo‑RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review

Citation: 2

Pesola, G., Epistolio, S., Cefalì, M., Trevisi, E., De Dosso, S., & Frattini, M. (2024). Neo‑RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review. Cancers, 16(23), 3923. https://doi.org/10.3390/cancers16233923 MDPIMDPIResearchGate

Summary:
This narrative review outlines the phenomenon of neo‑RAS wild‑type cancer, in which metastatic colorectal tumors originally harboring RAS mutations convert to wild‑type status during or after chemotherapy. The proposed mechanisms include selective depletion of RAS‑mutant clones and expansion of pre‑existing RAS wild‑type clones. The clinical implications concern eligibility for anti‑EGFR therapies in converted patients, with potential survival benefits. The review emphasizes the need for liquid biopsy monitoring, improved detection techniques, and further validation of outcomes such as progression‑free and overall survival Nature+7PubMed+7ResearchGate+7.

2. Biomarker Characterization in Endometrial Cancer in Europe: First Survey Data Analysis from 69 Pathological Academic and Hospital Labs

Citation: 6

Santoro, A., Bragantini, E., Castiglione, F., et al. (2024). Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs. Pathologica, 116(1), 32–45. https://doi.org/10.32074/1591‑951X‑926 PubMedPMC

Summary:
This multicentric observational study surveyed 69 European pathology labs (academic and hospital‐based) across Italy, Spain, Switzerland, and the UK regarding practices in molecular biomarker testing for endometrial cancer. It reports variability in the routine use of immunohistochemistry (e.g., MMR, p53) and molecular testing (such as POLE), highlighting heterogeneity in adoption. Barriers such as resource limitations and lack of standardization were noted, indicating a need for European‐wide guidelines and more uniform workflows PubliRES+5PMC+5ResearchGate+5.

3. Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis

Citation: 4

Clinical relevance and interplay between miRNAs in influencing glioblastoma multiforme prognosis (2025). CMBL (review article). MDPIPubMedMDPI

Summary:
This recent narrative/review article discusses how specific microRNAs modulate gene networks influential in glioblastoma multiforme (GBM) progression and patient prognosis. It stresses GBM’s dismal median survival (~12–15 months) and explores key miRNAs such as miR‑9 (oncogenic, associated with chemoresistance and poor survival), miR‑221/222 (promoting proliferation, angiogenesis), and tumor-suppressive miR‑181a/b. Emerging evidence around circulating miR‑29a, miR‑106a, and miR‑200a as prognostic markers is also highlighted. The article proposes miRNA profiles as potential biomarkers and therapeutic targets in GBM management Nature.

4. Antiandrogens as Therapies for COVID‑19: A Systematic Review

Citation: 3

(2023). Antiandrogens as Therapies for COVID‑19: A Systematic Review. Included original studies through August 2023. ResearchGatePMC

Summary:
This systematic review (covering March 2020 to August 2023) evaluates the evidence for antiandrogenic therapies—including androgen-deprivation therapy (ADT), 5‑alpha-reductase inhibitors, and antiandrogens like bicalutamide, enzalutamide, and proxalutamide—in improving COVID‑19 outcomes. Of 31 studies screened, results were mixed: proxalutamide showed potential in accelerating viral clearance and reducing hospitalizations in benign severity cases, but large-scale randomized data are lacking. Conversely, trials of enzalutamide and bicalutamide failed to show therapeutic benefit and raised safety signals—–bicalutamide is associated with increased mortality, particularly cardiovascular risk—suggesting antiandrogens are not broadly effective as COVID‑19 treatments ScienceDirect+4ResearchGate+4PMC+4.

🏁 Conclusion:

Dr. Milo Frattini exemplifies the qualities of an outstanding researcher—scientific excellence, translational impact, clinical relevance, and leadership. His contributions significantly advance molecular pathology and personalized cancer treatment. In the absence of formal international awards, his sustained academic, clinical, and editorial responsibilities clearly reflect peer recognition and influence. He is highly suitable and strongly recommended for the Best Researcher Award.

Pinglin li | Marine Natural Products | Best Researcher Award

Posted on 17/07/202517/07/2025 by The Scientist

Prof. Pinglin li | Marine Natural Products | Best Researcher Award

Professor at ocean university of China, China.

Dr. Li Pinglin is a distinguished professor at the School of Medicine and Pharmacy, Ocean University of China, with expertise in marine natural product chemistry. His research focuses on the isolation, structural elucidation, and bioactivity evaluation of secondary metabolites derived from marine invertebrates and their symbiotic microorganisms, especially from the South China Sea. He integrates advanced quantum chemical calculations such as ECD, NMR, and optical rotation analyses to decode complex molecular structures. With a prolific publication record in journals such as Marine Drugs, Phytochemistry, and Journal of Natural Products, Dr. Li has significantly contributed to the discovery of novel compounds with anti-inflammatory, anti-thrombotic, and cytotoxic properties. He has led several major national and provincial research projects and earned multiple scientific awards recognizing his innovative work. His academic journey is marked by a commitment to interdisciplinary research and excellence in marine-based pharmaceutical science.

Professional Profile:

✅Suitability For Best Researcher Award – Prof. Pinglin li

Dr. Li Pinglin is a seasoned and internationally recognized marine natural product chemist whose research lies at the intersection of organic chemistry, pharmacology, and computational analysis. With over a decade of academic and research leadership at the Ocean University of China, and an extensive list of peer-reviewed publications and awards, he demonstrates excellence in scholarly output, innovation, mentorship, and societal relevance. His continuous research support from national agencies and international exposure (e.g., Scripps Institution of Oceanography) strengthens his global profile.

🎓 Education

Dr. Li Pinglin earned his Ph.D. in Organic Chemistry in 2008 from Lanzhou University, China, one of the country’s top institutions in chemical sciences. Prior to this, he completed his Bachelor of Science in Chemistry in 2003 at the same university. His educational background laid a solid foundation in organic synthesis, molecular structure elucidation, and analytical chemistry. Dr. Li also broadened his scientific outlook through international academic exchange, serving as a visiting scholar at the prestigious Scripps Institution of Oceanography, University of California, San Diego, from 2015 to 2016, where he engaged in marine pharmacology and natural product chemistry.

💼 Experience

Dr. Li Pinglin has had a progressive academic career at the Ocean University of China. He began as a lecturer in the College of Food Science and Engineering (2008–2011) before transitioning to the School of Medicine and Pharmacy, where he served as a lecturer (2011–2013), associate professor (2014–2015), and has held the position of professor since January 2016. His long-standing affiliation with the university reflects deep institutional knowledge and leadership. He has supervised numerous graduate students and has contributed significantly to the growth of research in marine pharmacology, establishing himself as a core figure in the faculty’s scientific development.

📈 Professional Development

Throughout his career, Dr. Li has consistently advanced both his scientific expertise and professional influence. His research has been supported by prestigious funding bodies, including the National Natural Science Foundation of China and the Shandong Province Funds for Distinguished Young Scientists. As a chief investigator, he has led multiple competitive research projects and contributed to China’s growing leadership in marine bioprospecting. His professional development was further enriched during his tenure as a visiting scholar at the Scripps Institution of Oceanography, UCSD, where he engaged with global leaders in marine chemistry. Dr. Li has fostered interdisciplinary collaboration through his work on quantum-based stereochemical analysis and semi-synthesis of bioactive compounds. His publication record and award-winning contributions reflect continuous growth in scholarly impact and recognition. He remains committed to mentoring emerging scientists and contributing to the advancement of marine pharmacological sciences on both national and international fronts.

🔬 Research Focus

Dr. Li Pinglin’s primary research focus lies within Marine Natural Product Chemistry—an interdisciplinary field combining marine biology, organic chemistry, and pharmacology. His work involves the discovery, isolation, and structural characterization of secondary metabolites from South China Sea marine invertebrates, particularly soft corals and sponge-associated microorganisms. These natural compounds often display potent bioactivities, including anti-inflammatory, anti-thrombotic, cytotoxic, and antimicrobial effects, offering potential for pharmaceutical development. Dr. Li’s research also encompasses semi-synthetic modifications to enhance compound efficacy and stability. Additionally, his focus extends into computational chemistry, applying quantum methods such as ECD and NMR simulation to verify stereochemistry and chiral centers. This category of research plays a critical role in drug discovery, chemical ecology, and biomedical innovation. By bridging field exploration with molecular-level analysis, Dr. Li’s work contributes to unlocking the therapeutic potential of marine biodiversity and supporting sustainable marine drug development.

🧪 Research Skills

Dr. Li possesses a specialized skill set in natural product chemistry, particularly related to marine-derived compounds. His skills include advanced chromatographic isolation techniques (e.g., HPLC, LC-MS), spectroscopic structure elucidation (e.g., NMR, MS, IR), and quantum chemical calculations (e.g., ECD, NMR shift prediction, optical rotation) for stereochemical determination. He is adept at utilizing nuclear Overhauser effect spectroscopy (NOESY) and residual dipolar couplings (RDCs) to resolve challenging macrocyclic structures. Additionally, Dr. Li engages in semi-synthetic derivatization, enhancing the pharmaceutical potential of marine metabolites. His research relies on bioassay-guided fractionation, enabling targeted screening for anti-inflammatory, cytotoxic, and anti-thrombotic activities. He combines wet lab precision with computational chemistry to achieve accurate and efficient structural verification. These interdisciplinary skills are essential for modern drug discovery pipelines and chemical biology research, making Dr. Li a valuable expert at the intersection of marine science, organic chemistry, and medicinal chemistry.

🏅 Awards and Honors

Dr. Li Pinglin has received several prestigious awards in recognition of his outstanding research contributions. Notably, he was honored with the Sanofi Biopharmaceuticals Award for Youth by the Chinese Pharmaceutical Association in 2013, acknowledging his early-career excellence in drug-related research. He has also received multiple international academic awards from Sciencefarther and Scifax, India, including the Best Research Award from the 21st ACA Edition, Top Teachers Award in its 9th edition (TOT), and the Best Research Award in Advanced Nanomaterials and Nanotechnology (14th ANN Edition). These accolades highlight both his scientific innovation and teaching excellence, demonstrating national and global recognition. His award record affirms his sustained impact in natural product chemistry and his leadership in advancing marine-based therapeutic research.

Publication Top Notes

🧪 1. Discovery of Secondary Metabolites from the Sponge-Derived Fungus Aspergillus templicola

Journal: Marine Drugs
Date: July 2025
DOI: 10.3390/md23070285
Authors: Kai Li, Yue Zhang, Lei Li, Sen Wang, Cili Wang, Pinglin Li
Summary:
This study reports the isolation and structural elucidation of novel secondary metabolites from the sponge-associated fungus Aspergillus templicola. The research highlights their potential biological activities, including antimicrobial and cytotoxic properties, demonstrating marine fungi as promising sources of bioactive natural products.

🧬 2. Heterocycles and a Sorbicillinoid from the Coral-Derived Fungus Penicillium chrysogenum

Journal: Marine Drugs
Date: November 2024
DOI: 10.3390/md22110517
Authors: Junjie Yang, Yuan Zong, Cili Wang, Kai Li, Yue Zhang, Pinglin Li
Citation: 8 citations
Summary:
This paper explores the chemical diversity of Penicillium chrysogenum isolated from coral. It features the discovery of novel heterocyclic compounds and a sorbicillinoid derivative. Bioassays revealed antimicrobial and cytoprotective properties, highlighting their pharmacological relevance.

🌊 **3. Terpenoids from the Soft Coral Sinularia densa Collected in the South China Sea**

Journal: Marine Drugs
Date: September 2024
DOI: 10.3390/md22100442
Authors: Cili Wang, Jiarui Zhang, Kai Li, Junjie Yang, Lei Li, Sen Wang, Hu Hou, Pinglin Li
Citation: 2 citations
Summary:
The study identifies a series of terpenoid compounds from Sinularia densa, a soft coral species. Structural analysis and biological assays suggest these terpenoids exhibit promising bioactivities, especially in anti-inflammatory and anticancer screening platforms.

🧴 **4. Lemneolemnanes A–D, Four Uncommon Sesquiterpenoids from the Soft Coral Lemnalia sp.**

Journal: Marine Drugs
Date: March 2024
DOI: 10.3390/md22040145
Authors: Yuan Zong, Tian-Yun Jin, Jun-Jie Yang, Kun-Ya Wang, Xing Shi, Yue Zhang, Pinglin Li
Citation: 1 citation
Summary:
This article presents the isolation of four novel sesquiterpenoids named Lemneolemnanes A–D from Lemnalia species. The structural uniqueness and cytotoxic potential of these compounds reinforce the chemical richness of marine soft corals.

Conclusion

Dr. Li Pinglin exemplifies the ideals of a Best Researcher Award recipient. His innovative contributions to marine pharmacological sciences, especially his work in discovering and analyzing bioactive marine natural products, not only advance scientific understanding but also hold translational potential for human health. His blend of technical skill, research productivity, mentorship, and global recognition makes him a top-tier candidate deserving of the Best Researcher Award.

Julia Krebs | Sign Language Linguistics | Best Researcher Award

Posted on 15/07/202515/07/2025 by The Scientist

Assist. Prof. Dr. Julia Krebs | Sign Language Linguistics | Best Researcher Award

Assistant professor at University of Salzburg, Austria.

Dr. Julia Krebs 🎓 is an Assistant Professor in the Department of Linguistics at the University of Salzburg 🇦🇹, where she specializes in psycho-/neurolinguistics and sign language linguistics 🧠👐. She began her academic journey with certification as an Austrian Sign Language (ÖGS) interpreter, gaining practical insights that now shape her research. Dr. Krebs is known for pioneering work on the neural processing of sign language using EEG and motion capture techniques 📊🎥. She has published over 20 peer-reviewed articles 📚, co-authored a definitive handbook on ÖGS grammar 📘, and leads two Austrian Science Fund (FWF)-funded projects. Her interdisciplinary contributions span linguistics, cognitive neuroscience, and accessibility, promoting educational tools and enhancing societal recognition for sign language communities 🌍👩‍🏫. Collaborating with international scholars, her work significantly advances the theoretical and applied understanding of ÖGS. She is a rising leader in sign linguistics and cognitive processing research 🏆🌐.

Professional Profile:

Suitability For Best Researcher Award – Assist. Prof. Dr. Julia Krebs

Dr. Julia Krebs stands out as a rising leader in interdisciplinary linguistic research. Her unique combination of practical experience as a certified Austrian Sign Language (ÖGS) interpreter and her academic training in psycho-/neurolinguistics equips her to bridge theoretical insights with community needs. As an Assistant Professor, she has already made significant strides in applied research, neural processing of sign language, and educational accessibility. Her leadership in FWF-funded projects, her pioneering use of EEG and motion capture, and her substantial publication record demonstrate a strong and sustained research trajectory—especially remarkable at an early career stage.

🎓 Education

Dr. Krebs holds a Ph.D. in Psycho-/Neurolinguistics 🧠📖 from the University of Salzburg, where she continues her academic career. Her educational foundation is uniquely interdisciplinary—blending theoretical linguistics 📚, cognitive neuroscience 🧬, and practical communication through her formal certification as an Austrian Sign Language (ÖGS) interpreter 👐🇦🇹. This rare combination allows her to approach linguistic research from both empirical and experiential perspectives, integrating scientific rigor with community-centered insight. Her academic training empowers her to bridge the gap between language theory and applied research in the context of neurocognitive processing and sign language acquisition 🎓🔍.

🧑‍🏫 Experience

Dr. Julia Krebs serves as an Assistant Professor at the University of Salzburg’s Department of Linguistics 🏫📚. She has accumulated substantial experience in both teaching and research, focusing on sign language grammar, acquisition, and processing 🧠✍️. With roots as a professional ÖGS interpreter, she has a decade-long immersion in both practice and academia 👐👩‍🎓. Dr. Krebs has successfully led and collaborated on several major research projects, including EEG-based studies and motion capture investigations into sign language production 🎥💻. She works closely with international scholars and has contributed to curriculum development, interpreter education, and pedagogical strategies. Her contributions extend beyond research to real-world applications that empower the Deaf community and language educators alike 🌐👩‍🏫.

🚀 Professional Development

Dr. Krebs continually enriches her professional growth through advanced research collaborations, project leadership, and interdisciplinary integration 🌍🔬. She spearheads two major projects funded by the Austrian Science Fund (FWF), applying innovative techniques like motion capture and electromyography (EMG) to study sign language production 🎥⚡. A proactive member of academic societies including the Sign Language Linguistics Society (SLLS) and the Centre for Cognitive Neuroscience (CCNS) 🧠🌐, she stays at the forefront of emerging research. Dr. Krebs also engages in public science communication through co-authoring a seminal ÖGS grammar handbook and developing accessible educational materials 📘📢. Her professional path demonstrates a strong commitment to both advancing theoretical knowledge and fostering inclusive language education. As an early-career academic, she is building a global reputation through interdisciplinary research, co-authorship, and peer-reviewed publications 📚🤝, paving the way for future leadership in linguistics and cognitive science.

🔍 Research Focus

Dr. Julia Krebs’s research focus lies at the intersection of sign language linguistics, cognitive neuroscience, and language acquisition 🧠👐📘. Her primary domain is Austrian Sign Language (ÖGS), where she investigates grammar structures, agreement markers, and word order through both theoretical and experimental approaches 🧪📊. A notable aspect of her work is the use of dynamic EEG experiments and motion capture to study how the brain processes and produces sign language stimuli 🎥⚡. Her studies provide critical insights into how signed and spoken languages share cognitive mechanisms, like subject-preference in sentence processing 🗣️🧠. She also emphasizes how this scientific knowledge can improve language instruction and interpreter training, fostering accessibility and cultural recognition for the Deaf community 🧏‍♀️📚. Dr. Krebs’s research contributes both to the foundational understanding of human language and to applied linguistics, making her focus both innovative and socially impactful 💡🌍.

🧠Research Skills

Dr. Krebs is equipped with a powerful set of research skills spanning neurolinguistics, psycholinguistics, sign language analysis, and computational methodology 🔬📊. She excels in the design and execution of EEG experiments to study neural responses to linguistic stimuli 🧠💡. Additionally, she leverages motion capture and EMG to explore sign language production in real time, a rare and highly technical approach 🎥⚡. Her analytical expertise covers both quantitative and qualitative data interpretation, especially in syntactic and semantic analysis of ÖGS 📈📚. As a co-author of a grammar handbook, she demonstrates deep descriptive and applied linguistic competence. Her collaborative skills are also key—she effectively manages cross-disciplinary and international research teams 🤝🌐. Combined with strong academic writing and publication ability, Dr. Krebs’s toolkit enables her to make robust contributions to both theoretical and applied linguistics, helping to elevate the field of sign language linguistics globally 🚀✍️.

🏆Awards and Honors

Dr. Julia Krebs was honored with the Young Investigator Award 🎖️ by the University of Salzburg, recognizing her outstanding early-career achievements in linguistic research. Her co-authorship of the first comprehensive grammar handbook on Austrian Sign Language (ÖGS) 📘 was a landmark contribution to the field and has received national acclaim for its academic and social value 📚🏅. In addition to this prestigious institutional recognition, her leadership in FWF-funded research projects demonstrates her scholarly merit and research credibility at the national level 🇦🇹💼. Her groundbreaking work has gained attention in the scientific community and continues to earn accolades for its impact on both academia and the Deaf community 🧏‍♀️💬🌟.

Publication Top Notes

1. Age of acquisition effects differ across linguistic domains in sign language: EEG evidence

📌 Authors: E.A. Malaia, J. Krebs, D. Roehm, R.B. Wilbur
📅 Journal: Brain and Language, Vol. 200, 2020, Article 104708
📈 Citations: 31
🔍 Summary:
This study uses EEG (electroencephalography) to examine how the age of acquisition (AoA) of sign language impacts neural processing across different linguistic domains. The findings show that early and late learners of sign language exhibit significantly different neural responses when processing syntax, semantics, and morpho-syntactic elements, indicating that AoA has domain-specific effects on language processing in the brain.
🧠 Contribution: First electrophysiological evidence supporting domain-specific AoA effects in sign language users.

2. Subject preference emerges as cross-modal strategy for linguistic processing

📌 Authors: J. Krebs, E. Malaia, R.B. Wilbur, D. Roehm
📅 Journal: Brain Research, Vol. 1691, 2018, Pages 105–117
📈 Citations: 30
🔍 Summary:
This paper explores the “subject preference” strategy — the tendency to interpret ambiguous sentences as having a subject-first structure — in both spoken and signed languages. Using EEG, the study demonstrates that this strategy is a cross-modal linguistic feature, not limited to spoken languages, and applies to sign language as well.
🧠 Contribution: Supports the theory that certain parsing strategies are modality-independent, reflecting universal cognitive-linguistic principles.

3. Age of sign language acquisition has lifelong effect on syntactic preferences in sign language users

📌 Authors: J. Krebs, D. Roehm, R.B. Wilbur, E.A. Malaia
📅 Journal: International Journal of Behavioral Development, Vol. 45(5), 2021, Pages 397–408
📈 Citations: 22
🔍 Summary:
This behavioral study investigates how AoA influences syntactic preferences in adult sign language users. Findings suggest that early exposure leads to more native-like preferences for canonical word order, whereas later learners demonstrate alternative syntactic strategies.
🧠 Contribution: Emphasizes the long-term syntactic impact of AoA in signed languages, with implications for education and cognitive development in deaf individuals.

4. Interaction between topic marking and subject preference strategy in sign language processing

📌 Authors: J. Krebs, E. Malaia, R.B. Wilbur, D. Roehm
📅 Journal: Language, Cognition and Neuroscience, Vol. 35(4), 2020, Pages 466–484
📈 Citations: 18
🔍 Summary:
This research explores how topic marking interacts with the subject preference parsing strategy in sign language. Using EEG, the study shows that topic marking can override the default subject-first strategy, demonstrating the dynamic nature of syntactic processing in sign language.
🧠 Contribution: Offers insights into hierarchical cue processing and discourse-level structure in signed languages.

5. The impact of transitional movements and non-manual markings on the disambiguation of locally ambiguous argument structures in Austrian Sign Language (ÖGS)

📌 Authors: J. Krebs, R.B. Wilbur, P.M. Alday, D. Roehm
📅 Journal: Language and Speech, Vol. 62(4), 2019, Pages 652–680
📈 Citations: 17
🔍 Summary:
This paper investigates how non-manual cues (e.g., facial expressions) and transitional hand movements help disambiguate syntactic ambiguity in Austrian Sign Language. Results show that signers rely heavily on these multimodal features for parsing sentence structure.
🧠 Contribution: Highlights the role of multimodal information in syntactic disambiguation and emphasizes the complexity of visual-spatial grammar.

Conclusion

Dr. Julia Krebs exemplifies the profile of a Best Researcher Award recipient: innovative, impactful, interdisciplinary, and community-engaged. Her scientific work not only advances core knowledge in neurolinguistics and sign language linguistics but also translates into real-world benefits—educationally, socially, and technologically. She is not only contributing to academia but also reshaping how we understand and support sign language users in society.

Huanling Lai | Anti-cancer | Best Researcher Award

Posted on 15/07/202515/07/2025 by The Scientist

Assoc. Prof. Dr. Huanling Lai | Anti-cancer | Best Researcher Award

Assoc. Prof. at Guangzhou National Laboratory, China.

Dr. Huanling Lai 🇨🇳 is an accomplished Associate Professor at Guangzhou Laboratories specializing in pharmacology, traditional Chinese medicine, and neuroscience. Her research bridges ancient medicinal wisdom with modern molecular approaches, focusing on lung cancer therapeutics, brain neural discharge mechanisms, and multi-omics-based pharmacological exploration 🔬🧠🌿. With over 25 high-impact journal publications, multiple patents 🧾, and leadership in nationally funded research projects, she exemplifies innovation and academic rigor. A key member and editor in numerous scientific journals and organizations 🌐📚, she contributes actively to the global pharmacology and neurology research community. Her translational research has led to the development of novel diagnostics and therapeutic pathways. Dr. Lai continues to inspire with her dedication to scientific advancement and medical integration, making her a strong candidate for international recognition in research excellence 🏆🔎.

Professional Profile:

🏆Suitability for Best Researcher Award – Assoc. Prof. Dr. Huanling Lai

Dr. Huanling Lai exemplifies the ideal candidate for a Best Researcher Award through her integrative and translational research that merges traditional Chinese medicine (TCM) with cutting-edge molecular pharmacology and neuroscience. She has demonstrated outstanding scientific leadership, innovation, and societal impact in the areas of lung cancer treatment, epilepsy neuropharmacology, and multi-omics drug mechanism elucidation. Her ability to bridge ancient medicinal wisdom with modern biomedical science not only enhances global pharmacological understanding but also contributes directly to developing novel therapeutics and diagnostic technologies.

🎓 Education

Dr. Lai began her academic journey in Chinese Medicine at Guangdong Pharmaceutical University (2006–2010) 🏫📜, earning a Bachelor of Science. She then pursued a Ph.D. in Pharmacology of Chinese Medicines at Guangzhou University of Traditional Chinese Medicine (2010–2015) 🎓🧪. Her doctoral studies integrated biomedical research techniques with the philosophy of traditional Chinese therapeutics, laying the groundwork for her multidisciplinary expertise in pharmacological mechanisms and disease treatment. Her education reflects a fusion of traditional practices with cutting-edge scientific inquiry 🌿🧬.

🧪 Professional Experience

Dr. Lai’s research career spans prestigious institutions and collaborative platforms 🧑‍🔬🏢. Since 2021, she serves as Associate Professor at Guangzhou Laboratories in the Basic Research Department 🏥. She briefly held the same role at BioIsland Laboratories (2020–2021), where she focused on neurometabolism. From 2017 to 2020, she undertook rigorous postdoctoral training under renowned mentors including Academician Liang Liu and Prof. Elaine Lai-Han Leung at the State Key Laboratory of Quality Research in Chinese Medicines (Macao University of Science and Technology) 🌍. Her experience has equipped her with expertise in multi-omics, neuroscience, molecular pharmacology, and oncology, with a strong record of collaborative research and translational innovation 🧠🔬📈.

📈 Professional Development

Dr. Lai is deeply involved in academic service, collaboration, and innovation. She holds editorial roles as Guest Editor for Frontiers in Nutrition and Pharmacology 📝. She serves on reviewer panels for several prestigious journals including Current Neuropharmacology, Annals of Medicine, BMC Pharmacology, and Frontiers in Oncology 🔍📚. She is also a Director at the Guangdong Anti-Epilepsy Association, and an active member of organizations like the World Federation of Chinese Medicine and Chinese Anti-Epilepsy Association 🌐. Her involvement in multidisciplinary societies strengthens academic networking and professional knowledge sharing. These roles reflect her commitment to scientific dissemination, peer review, and professional ethics, while enhancing her leadership within both the pharmacological and neurological communities 🌟🤝.

🔬 Research Focus

Dr. Lai’s research primarily focuses on Translational Pharmacology bridging Traditional Chinese Medicine (TCM) 🌿 and modern molecular biology 🔬. Her work encompasses three core areas: (1) elucidating the molecular mechanisms of TCM formulations, (2) investigating small molecule drug action against lung cancer, and (3) decoding the neural discharge mechanisms in epilepsy using multi-omics approaches 🧠💊. She integrates phytomedicine, oncology, and neuroscience to develop innovative therapies, particularly those enhancing immunotherapy efficacy and modulating ion transport mechanisms in brain disorders. Her research is at the interface of natural product pharmacology, neuropharmacology, and precision oncology, reflecting strong interdisciplinary depth and clinical relevance 🧫🧘‍♀️⚕️.

🧠Research Skills

Dr. Lai possesses a robust skill set in molecular pharmacology, multi-omics analysis, and neurophysiological diagnostics 🔍🧬. She is skilled in drug mechanism modeling, pharmacodynamic assays, and bioinformatics to explore disease mechanisms at both cellular and systems levels. Her expertise in using TRPV1/TRPV2 ion channel models, phosphoproteomics, and EEG signal processing demonstrates her technical versatility in bridging lab science with clinical applications 🧠📊. Additionally, she has developed AI-assisted methods for automatic detection of high-frequency oscillations in EEG, patenting multiple innovations in this space 🖥️🧠. Her strengths include experimental pharmacology, natural compound screening, cancer pathway signaling, and gut-brain axis investigations, reflecting a comprehensive toolkit to tackle complex biomedical challenges 🧪🔬💡.

🏅Awards and Honors

Dr. Lai has been recognized through multiple national and provincial-level research grants, including from the National Natural Science Foundation of China, Guangdong Provincial Foundation, and Guangzhou Science & Technology Bureau 🏆💰. Her role as Principal Investigator in high-impact projects on lung cancer immunotherapy and epilepsy neuropharmacology highlights her leadership and innovation. She holds five authorized patents, including devices for EEG analysis and traditional medicine formulations, demonstrating both academic and translational impact 🧠📄. As a Director of the Guangdong Anti-Epilepsy Association and an editor/reviewer for top-tier journals, she is also recognized as a leader in professional service. These accolades reflect her reputation for excellence in research, clinical relevance, and scientific integrity 🌟📜.

Publication Top Notes

1. Title: Berbamine as potential STING inhibitor for KRAS-mutant non-small cell lung cancer

Title: Berbamine as potential STING inhibitor for KRAS-mutant non-small cell lung cancer
Journal: Pharmacological Research, 2025
Summary:
This study examines the therapeutic potential of berbamine, a natural compound, in KRAS-mutant non-small cell lung cancer (NSCLC). The researchers demonstrated that berbamine effectively inhibits the STING signaling pathway, which is often associated with tumor-promoting inflammation in KRAS-mutated cancers. Suppression of STING activity by berbamine led to reduced cancer cell viability and tumor growth. The results highlight berbamine as a promising STING-targeted therapy for a difficult-to-treat subtype of NSCLC.

2. Title: Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer

Title: Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer
Journal: Phytomedicine, 2024
Citation Count: 12
Summary:
This paper explores the antitumor properties of Tanshinone IIA, a compound derived from traditional Chinese medicine. The researchers found that it induces endoplasmic reticulum (ER) stress and activates the JNK pathway, leading to cancer cell death and inhibition of tumor growth in NSCLC models. Furthermore, Tanshinone IIA enhanced the efficacy of anti-PD-1 immunotherapy, suggesting its potential as a combination agent to improve immune-based treatment responses in NSCLC patients.

✅ Conclusion

Dr. Huanling Lai stands out as a pioneering pharmacologist with exceptional interdisciplinary reach, innovation capacity, and societal relevance. Her career reflects a seamless integration of research excellence, technical sophistication, and translational impact. These qualities make her not only eligible but highly deserving of a Best Researcher Award at the national or international level.

Mohammad Suhail Meer | Geoinformatics | Best Researcher Award

Posted on 13/07/202513/07/2025 by The Scientist

Dr. Mohammad Suhail Meer | Geoinformatics | Best Researcher Award

Assistant Professor at Health GIS Laboratory, Department of Respiratory Medicine Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, 602105, Tamil Nadu, India

Dr. Mohammad Suhail Meer 🇮🇳 is a dedicated researcher in geospatial science, specializing in environmental and disaster applications 🌍📡. With a Ph.D. in Geoinformatics from Sathyabama Institute of Science and Technology 🎓, his research bridges satellite remote sensing, climate change, and environmental monitoring. He is particularly passionate about cyclone and precipitation mapping 🌪️🌧️, flash flood forecasting 🌊, land use/land cover change detection 🌱🏙️, health GIS modeling 🏥🗺️, and microplastic pollution assessment 🧪🌊. Guided by a leading scientist from the India Meteorological Department, his doctoral thesis focused on the relationship between land use changes and their societal and environmental impacts in North Kashmir. Dr. Meer is known for his interdisciplinary outlook and aims to contribute meaningfully to sustainable development, disaster resilience, and geospatial innovation. He blends scientific rigor with practical impact, striving for excellence in every step of his research journey 🚀📖.

Professional Profile:

✅Suitability For Best Researcher Award – Dr. Mohammad Suhail Meer

Dr. Mohammad Suhail Meer exemplifies a well-rounded researcher with:

A solid academic background in Geoinformatics, Disaster Management, and Environmental Sciences 🎓🌍
Interdisciplinary expertise that bridges environmental monitoring, climate science, health GIS, and pollution analysis 🧪🏥🛰️
Technical mastery in satellite remote sensing, GIS modeling, and spatial data analysis 🖥️🗺️
A regional research focus on climate-sensitive areas (North Kashmir), contributing critical insights to local and global environmental resilience plans ⛰️🌦️
A strong alignment with UN Sustainable Development Goals (SDGs)—especially SDG 13 (Climate Action), SDG 11 (Sustainable Cities), and SDG 3 (Good Health) 🌆🌱

🎓 Education

Dr. Meer has a solid educational foundation in geospatial and environmental sciences 📚. He earned his Ph.D. in Geoinformatics 🛰️ from Sathyabama Institute of Science and Technology in 2022, focusing on land use and environmental interactions in North Kashmir. He previously completed a Master’s in Disaster Management 🌪️ from Indira Gandhi National Open University in 2017 and an M.Sc. in Geoinformatics 🌍 from the University of Kashmir in 2014. His undergraduate studies included Geology, Geography, Chemistry, and English 🧪🗺️📘 from the University of Kashmir (2011), providing a multidisciplinary base. Additionally, he holds a Diploma in Computer Applications 💻 from the International Computer Institute (2007), showcasing his technical proficiency in software and data tools essential for GIS-based analysis.

💼 Experience

While his formal CV focuses more on academic credentials, Dr. Meer has built a strong foundation through research-intensive academic work and field-based projects 🧑‍🔬📊. His doctoral journey included satellite data analysis, modeling of flash floods, and environmental monitoring in climate-sensitive areas such as North Kashmir 🏔️🌧️. Working under the mentorship of a senior scientist from the India Meteorological Department 🌦️, he gained hands-on experience in remote sensing applications, meteorological analysis, and GIS-based policy implications. His field knowledge and geospatial expertise enable him to provide meaningful insights into disaster management, health GIS, and pollution tracking 🌪️📍. Dr. Meer continues to expand his experience in both academic research and applied science, with a vision to contribute to global environmental sustainability 🌱🌐.

📈 Professional Development

Dr. Mohammad Suhail Meer is consistently engaged in upgrading his professional capabilities through academic research, skill enhancement, and multidisciplinary exploration 🧑‍🏫💡. His Ph.D. journey refined his technical command of satellite data interpretation, GIS modeling, and environmental impact studies 🛰️🗺️. He has also pursued post-graduate training in Disaster Management, equipping him with an understanding of crisis response frameworks and resilience strategies ⚠️📘. His diploma in Computer Applications further sharpened his technical proficiency in geospatial tools and programming environments 💻📊. Dr. Meer actively follows developments in climate science, microplastic research, and health-environment interactions 🧪🌍. He aspires to collaborate across disciplines and institutions to broaden the impact of his work. His learning journey emphasizes not only scientific advancement but also societal benefit, demonstrating his commitment to sustainable development, innovation, and practical solutions for global challenges 🌎🤝.

🔬 Research Focus

Dr. Meer’s research falls under Environmental Geoinformatics and Disaster Risk Science 🌍🌪️. His work primarily revolves around remote sensing applications in climate and environmental change, with key emphasis on cyclone tracking, precipitation patterns, flood forecasting, and land use/land cover dynamics 🛰️🌧️🌊🌱. He integrates satellite imagery and GIS modeling to evaluate environmental transformations and their links with human systems 🗺️🏘️. Additionally, he explores emerging threats like microplastic pollution in ecosystems 🌊🧪 and applies Health GIS to analyze spatial impacts on public health 🏥📍. His regional focus on North Kashmir—a climate-sensitive and topographically complex area—makes his research crucial for climate adaptation, sustainability, and resilience planning ⛰️🌦️. Dr. Meer’s work contributes to SDGs related to climate action, clean environments, and sustainable cities 🚀🌆. He aligns technical expertise with societal priorities, establishing himself as a rising voice in geospatial environmental research 🌐🔍.

🛠️ Research Skills

Dr. Mohammad Suhail Meer possesses a diverse skill set in Geoinformatics, Remote Sensing, and Environmental Modeling 🛰️🗺️. His technical expertise includes processing satellite imagery, GIS-based spatial analysis, climate data forecasting, flood modeling, and LULC detection 🌀🌧️🌿. He is proficient in using tools like ArcGIS, ERDAS Imagine, QGIS, and remote sensing software suites 🖥️📊. His interdisciplinary training in disaster management enhances his ability to model risk zones and develop mitigation strategies ⚠️📍. His experience in Health GIS and microplastic pollution tracking reflects his adaptability in both human and ecological domains 🏥🌊. With a diploma in Computer Applications, Dr. Meer also brings coding and data processing capabilities essential for complex spatial analysis 💻📈. His research integrates satellite data, environmental indicators, and policy relevance, making him adept at solving real-world problems through spatial intelligence and scientific innovation 🌍🧠.

🏅 Awards & Honors

While no formal awards or honors are listed in the provided CV 🗃️, Dr. Mohammad Suhail Meer’s Ph.D. research under the supervision of a senior India Meteorological Department scientist 🌦️🧑‍🔬 signifies a high level of academic recognition and institutional trust. His successful completion of interdisciplinary degrees and sustained commitment to environmental and disaster science reflect academic distinction and research potential 🎓💫. As he continues publishing and contributing to scientific communities, Dr. Meer is well-positioned for future recognition in areas like environmental sustainability, GIS innovation, and disaster management 🌱🏆.

Publication Top Notes

Satellite-based assessment of extreme rainfall during the 2019 Indian monsoon: climatic linkages to IOD and ENSO

Journal: Modeling Earth Systems and Environment
Publication Year: 2025
Summary:
This study employs satellite-based data to analyze extreme rainfall events during the 2019 Indian monsoon season. It investigates how large-scale climate phenomena—particularly the Indian Ocean Dipole (IOD) and El Niño-Southern Oscillation (ENSO)—influenced monsoonal rainfall patterns.
Key Topics:
- Extreme rainfall analysis
- Satellite remote sensing
- Indian monsoon 2019
- Climatic drivers: IOD & ENSO

A Review on Enhancing Flood Mitigation Strategies: A Comparative Study of SCS-CN and ANN Model Integration with GIS for Rainfall–Runoff Simulation

Type: Review Paper
Summary:
This review compares the effectiveness of two popular hydrological models—SCS-Curve Number (SCS-CN) and Artificial Neural Networks (ANN)—when integrated with Geographic Information Systems (GIS) for simulating rainfall-runoff processes. It aims to identify the best model combinations for improving flood mitigation strategies.
Key Topics:
- Rainfall–runoff modeling
- SCS-CN vs. ANN
- GIS-based hydrological simulations
- Flood mitigation and water resource planning

🏁 Conclusion

Dr. Mohammad Suhail Meer is not only an emerging expert in environmental geospatial science but also a researcher with deep societal relevance, interdisciplinary vision, and technical innovation. Though he is at an early stage of his recognition journey (with formal awards yet to come), his work already reflects the qualities of excellence, originality, and impact that define a Best Researcher Award recipient.

Sumayah Al-Mahmood | Pharmaceutical | Best Researcher Award

Posted on 11/07/202511/07/2025 by The Scientist

Mrs. Sumayah Al-Mahmood | Pharmaceutical | Best Researcher Award

Lecturer at Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Department of Basic Sciences, College of Dentistry, Al-Iraqia University, Iraq.

Dr. Sumayah Abid Al-Mahmood 🇮🇶 is a passionate pharmaceutical scientist specializing in nanotechnology, drug formulation, and drug delivery systems 💊🧪. Currently a PhD candidate at the University of Baghdad 🏛️, she also holds a Master’s in Pharmaceutical Sciences from Rutgers University, USA 🇺🇸 and a Bachelor’s degree from Tikrit University 🎓. With over 17 publications, 431 citations, and an emerging H-index of 3, her research contributions span innovative topical, oral, and transdermal delivery technologies. Dr. Sumayah has served as an instructor and lab supervisor 🧑‍🏫, clinical pharmacist 💉, and student coordinator 🎯. Her work addresses both local and global pharmaceutical challenges, including COVID-19, oral cancer, and antifungal therapies. She is also an active member of AAPS and the Iraqi Pharmacy Syndicate 🌍. Her commitment to education, research, and healthcare makes her a strong candidate for the Best Researcher Award 🏅.

Professional Profile:

🏅Suitability For Best Researcher Award – Mrs. Sumayah Al-Mahmood

Dr. Sumayah Abid Al-Mahmood brings a compelling combination of academic rigor, international training, and impactful research in pharmaceutics. Her specialization in nanotechnology-based drug delivery systems addresses both foundational science and real-world healthcare needs, such as COVID-19, cancer therapy, and antifungal treatments. With over 17 publications, 431 citations, and a rising H-index, she demonstrates a growing influence in her field. Additionally, her cross-continental education—from Rutgers University, USA to the University of Baghdad—underscores her global outlook and adaptability. Her long-standing commitment to teaching, mentorship, and clinical practice further strengthens her profile as a well-rounded and impactful researcher.

🎓 Education

Dr. Sumayah Abid Al-Mahmood’s academic journey reflects a blend of local dedication and international excellence 🌍. She is currently pursuing her PhD in Pharmaceutics at the University of Baghdad, Iraq 🏛️. She earned her Master of Pharmaceutical Sciences from Rutgers University, USA in 2016 🎓🇺🇸, gaining advanced expertise in drug delivery technologies and research methodologies. Her foundational degree, Bachelor of Pharmacy, was awarded by Tikrit University, Iraq in 2007 💊🇮🇶. Through these institutions, she developed deep knowledge in molecular pharmaceutics, dermaceutics, and engineered drug systems 🧬🧪, shaping her into a capable and forward-thinking researcher.

🧑‍🏫 Experience

Dr. Sumayah brings over 15 years of diverse professional experience in academia, healthcare, and pharmaceutical science 🔬. She currently serves as an Instructor at University of Al-Iraqia (2018–present) 🏫, teaching courses like pharmacology and medical terminology. Earlier, she worked as a Laboratory Supervisor at Tikrit University (2008–2013) 🔍, where she instructed biopharmaceutics and pharmaceutical chemistry. From 2008–2009, she practiced as a Clinical Pharmacist at Tikrit Hospital 🏥, delivering care across departments including pediatrics and surgery. Additionally, she plays a key role in student coordination at the College of Dentistry 🎓, reflecting her leadership and mentorship abilities.

📚 Professional Development

Dr. Sumayah is committed to continuous growth through professional training and academic engagement 📈. She participated in multiple teaching assistant workshops at Rutgers University, including courses in poster design, Excel grading, and digital communication 💻📝. She holds a CPR AED certificate from the American Heart Association and the Internet and Computer Core Certification (IC3) from 2010 💾🛡️. A student member of the American Association of Pharmaceutical Scientists (AAPS) from 2013–2016 and a long-time member of the Iraqi Pharmacy Syndicate 🧑‍🔬🇮🇶, she actively contributes to professional communities. Her fluency in Arabic 🗣️ and technical proficiency with MS Office tools help her in both research and instruction. These credentials demonstrate her dedication to evolving with scientific advances and pedagogical innovations 🌐📖.

🔬 Research Focus Area

Dr. Sumayah’s research is focused on pharmaceutics, particularly in the development of innovative drug delivery systems 💊. Her work explores nanotechnology-based carriers such as ufasomes, solusomes, and buccal films, targeting enhanced bioavailability and controlled release 🧬🔄. She has published extensively on transdermal, nasal, and oral delivery techniques, with therapeutic applications ranging from antifungal agents to CNS-targeting drugs 🧠⚕️. Her research also addresses public health concerns, including COVID-19 vaccine acceptance, oral cancer treatment, and antibiotic resistance 🦠💉. By combining laboratory techniques with clinical relevance, she contributes to both pharmaceutical innovation and public health betterment. Her publications across journals like OpenNano, Current Drug Delivery, and Drug Delivery & Translational Research reflect the translational value of her work. Thus, her research fits squarely in the “Drug Delivery and Pharmaceutical Nanotechnology” category 🧪🏅.

🧠 Research Skills Category

Dr. Sumayah demonstrates expertise across a range of advanced pharmaceutical research skills 🧪. These include formulation development, nanoparticle preparation, mucoadhesive systems, and thermosensitive gel design ⚗️🧬. She is adept in in vitro, ex vivo, and optimization studies, often using response surface methodology for formulation tuning 📊🧠. Her analytical skills extend to statistical research design, literature review, and writing for publication, supported by coursework in molecular pharmaceutics and membrane transport 🧾📚. She also explores phytochemistry, antimicrobial resistance, and oral health science, revealing her interdisciplinary capabilities. Her digital competencies, such as Microsoft tools and scientific software, further enhance her lab and teaching productivity 💻📈. As such, her skills align with the “Formulation Science, Drug Delivery Engineering, and Translational Pharmaceutics” category, bridging bench science and clinical application effectively 🧫💊.

🏅 Awards and Honors

While Dr. Sumayah has not listed formal awards, her achievements reflect high academic and research merit 🏆. Publishing 17 peer-reviewed articles, contributing to global conferences, and earning over 430 citations 📑🌐 positions her as a recognized scholar in pharmaceutics. Her publications in high-visibility journals and consistent research output indicate a growing influence in nanotechnology-driven drug delivery. She earned her Master’s degree from Rutgers University, a prestigious U.S. institution 🇺🇸🎓, reflecting international academic distinction. As a nominee for the Best Researcher Award, her multidisciplinary impact, publication record, and dedication to pharmaceutical sciences demonstrate excellence worthy of formal recognition 🥇📘.

Publication Top Notes

📘 1. Metastatic and Triple-Negative Breast Cancer: Challenges and Treatment Options

Authors: S. Al-Mahmood, J. Sapiezynski, O.B. Garbuzenko, T. Minko
Journal: Drug Delivery and Translational Research, 2018, Vol. 8, pp. 1483–1507
Citations: 611
Summary:
This highly cited review discusses the complexities of treating metastatic and triple-negative breast cancer (TNBC), a subtype with poor prognosis. It evaluates emerging nanotechnology-based drug delivery systems, molecular targets, and personalized therapies aimed at improving outcomes for TNBC patients.

📘 2. Acceptance of COVID-19 Vaccine Among General Population in Iraq

Authors: H. Faisal Ghazi, T. Taher Mohammed Jwad, S. Abdul Lateef Alfadhul, S. Al-Mahmood, et al.
Journal: Iraqi National Journal of Medicine, 2021, Vol. 3(1)
Citations: 21
Summary:
This study explores public perception, barriers, and willingness to receive the COVID-19 vaccine among Iraq’s general population. It provides data on factors influencing vaccine acceptance, helping to guide public health strategies and communication during pandemics.

📘 3. Comparative Evaluation of the Effectiveness of 40% Miswak Mouthwash and 0.12% Chlorhexidine Mouthwash in Treating Gingivitis: A Blinded, Randomised Clinical Trial

Authors: S. Al-Mahmood, D. Wadeea Sabea
Journal: Oral Health & Preventive Dentistry, 2021, Vol. 19(1), pp. 229–233
Citations: 9
Summary:
This randomized clinical trial compares the efficacy of a natural Miswak-based mouthwash with a standard chlorhexidine rinse in gingivitis treatment. Results indicate that Miswak may serve as a cost-effective and culturally acceptable alternative with fewer side effects.

📘 4. Microbiological Profile with Antibiotic Resistance Pattern in Patients of Pneumonia in Iraq

Authors: A.I. Jaaffar, S. Al-Mahmood, R.K. Maeh, M. Alyasiry
Journal: Drug Invention Today, 2019, Vol. 11(11), pp. 2913–2916
Citations: 7
Summary:
This paper provides microbiological analysis and resistance profiles of pathogens isolated from pneumonia patients in Iraq. It highlights the growing issue of antibiotic resistance, aiding clinicians in selecting more effective empirical therapies.

📘 5. Estimation of the Antibacterial Effect of Curcumin and Rosemary Among Patients with Dental Caries In Vitro

Authors: E. Al-Sharifi, A. Al-Mahmood, S. Al-Mahmood
Journal: Asian Journal of Pharmaceutical and Clinical Research, 2019, Vol. 12(3), pp. 277–279
Citations: 4
Summary:
This in vitro study evaluates the antibacterial efficacy of curcumin and rosemary extracts against bacteria causing dental caries. The findings support the potential of these natural agents as adjuncts in oral healthcare products.

✅ Conclusion

Dr. Sumayah Abid Al-Mahmood exemplifies the values of the Best Researcher Award through her scientific innovation, academic dedication, international credentials, and contributions to global health challenges. Her work not only pushes the boundaries of pharmaceutical research but also directly translates into societal benefit. With her strong publication record, cross-sectoral experience, and future research potential, she is highly deserving of this award recognition. 🏆💊🌍

Rameeza Andleeb | Behavioral Finance | Best Researcher Award

Posted on 09/07/202509/07/2025 by The Scientist

Dr. Rameeza Andleeb | Behavioral Finance | Best Researcher Award

Assistant Professor at National University of Computer and Emerging Science, Pakistan.

Dr. Rameeza Andleeb 🎓 is a finance academic and researcher currently serving as an Assistant Professor at FAST National University, Islamabad 🇵🇰. She holds a PhD in Finance from the Capital University of Science & Technology (2024) and has contributed significantly to the fields of behavioral finance, investor sentiment, and fintech 📊💡. With a strong record of research publication in reputable journals like PLOS ONE, SAGE Open, and Asia-Pacific Financial Markets 📚, Dr. Rameeza is emerging as a promising voice in academic finance. Her professional journey also includes mentoring students, reviewing scholarly papers, and participating in innovative AI-based finance research 🤖📈. Her contributions reflect a blend of academic excellence, collaborative spirit, and passion for technological integration in finance 🌐. With a commitment to professional development and community service, she continues to make meaningful strides in both teaching and research arenas 🌟.

Professional Profile

Suitability For Best Researcher Award – Dr. Rameeza Andleeb

Dr. Rameeza Andleeb exemplifies the qualities expected from a recipient of a Best Researcher Award. Her academic rigor, multidisciplinary knowledge, and consistent research output position her as a rising thought leader in behavioral finance and fintech. Her scholarly activities—including peer-reviewed publications, reviewing for internationally recognized journals, and leadership in AI-integrated finance projects—demonstrate her commitment to advancing knowledge in both theoretical and applied finance. Her focus on cutting-edge themes like investor sentiment and AI in finance makes her research both relevant and forward-looking.

Education

Dr. Rameeza Andleeb‘s academic journey is a testament to her dedication to continuous learning 📖🎓. She earned her PhD in Finance in 2024 from the Capital University of Science & Technology 🏛️. She previously completed her MS in Finance from International Islamic University Islamabad in 2015 📊. Alongside her finance specialization, she pursued an M.A/M.Ed in Distance and Non-Formal Education in 2013 from AIOU 🎒, demonstrating a cross-disciplinary interest in education. She also holds an M.Com in Accounting & Finance (2011) 📚, a B.Ed (2009) 👩‍🏫, and a B.Com (2009) 💼 from leading Pakistani institutions. Her academic record reflects a deep and evolving commitment to finance and education across multiple disciplines, equipping her with a holistic understanding of both theory and practice.

Experience

Dr. Rameeza Andleeb brings extensive academic and professional experience to the table 💼. She is currently an Assistant Professor at FAST NUCES Islamabad (2024–present) 🏫. Previously, she served as a Lecturer at ARID Agriculture University, University of Gujrat, and University of Central Punjab from 2015 to 2023 📘. Her earlier career includes roles as an invigilator at the British Council and a supervisor with NTS 📝. In the banking sector, she interned at the Bank of Punjab in 2009 🏦. She also has five years of teaching experience at Almasharqi High School and College, showing her early dedication to education 👩‍🏫. Her diverse background in both higher education and academic support roles contributes to her strong teaching and mentoring abilities .

Professional Development

Dr. Rameeza Andleeb is actively involved in professional development through continuous research, academic service, and skill-building initiatives 📈📚. She mentors students at FAST through its Community Services Society, promoting leadership and social responsibility 💬👥. Her participation in a Faculty Research Support Grant (FRSG) project—focused on AI and stock trading—demonstrates her commitment to integrating cutting-edge technology with finance 🤖💹. As a peer reviewer for journals like PLOS ONE and SAGE Open, she contributes to academic rigor and scholarly discourse 📑🔍. With over 30 reviewed papers, she plays a crucial role in quality control within the academic finance community 🧠. Her engagement in research and teaching alongside community service reflects a well-rounded and growth-oriented professional profile 🌱. Whether through mentoring, publishing, or contributing to innovative research, she continually strives for excellence and relevance in her field 🌟.

Research Focus Category

Dr. Rameeza Andleeb’s research focuses on Behavioral Finance, Investor Sentiment Analysis, and Fintech Adoption 📊💬. Her work primarily explores how psychological factors and market behavior influence equity returns, especially in emerging markets 📉📈. She examines nonlinear effects of investor emotions, reactions to global events, and their relationship with market volatility 🌍📉. Additionally, her recent interest includes the role of AI and large language models in stock market decision-making, demonstrating a strong inclination toward Tech-Integrated Finance Research 🤖💡. Dr. Rameeza’s publications show a blend of theoretical models and practical implications, helping policymakers, investors, and academics better understand market anomalies and behavioral trends 🧠📊. This multidisciplinary and applied research focus makes her a valuable contributor in the fields of economics, finance, and digital transformation 🔄💼.

Research Skills Category

Dr. Rameeza Andleeb possesses a diverse set of research skills that elevate her scholarly impact 🧠📈. She is proficient in quantitative research methods, especially econometric modeling, time-series analysis, and sentiment quantification tools 📊📉. Her ability to merge finance theories with statistical models enables her to extract insights from complex financial behaviors and market data 🧮💹. In recent projects, she has worked on AI-driven financial models, showing her adaptability to emerging technologies like LLMs and autonomous agents 🤖📘. Her peer-review work for prestigious journals further highlights her critical thinking, analytical depth, and commitment to research integrity 📑✔️. She also has a keen understanding of behavioral biases, fintech usability, and investor psychology, supporting her niche in Behavioral Finance 🎯. Her skills span research design, literature synthesis, and multi-author collaboration, making her a strong research team contributor and independent scholar alike 🤝🌐.

Awards and Honors

While formal awards are not explicitly listed, Dr. Rameeza Andleeb’s achievements reflect recognition in multiple academic forums 🏆📘. Her selection as a peer reviewer for globally recognized journals like PLOS ONE and SAGE Open signifies high academic trust and prestige 🎓🔍. Her leadership in an AI-finance FRSG project also positions her as a forward-thinking researcher selected for institutional support 🚀💰. Additionally, her inclusion in multi-author, multi-disciplinary papers with international collaborators demonstrates peer recognition and professional credibility 🌍🤝. Though she may not yet hold traditional honors or medals, her research contributions, mentoring roles, and active academic engagement mark her as an emerging scholar deserving of future accolades ⭐📈.

Publication Top Notes

1. Predictive Effect of Investor Sentiment on Current and Future Returns in Emerging Equity Markets

Authors: R. Andleeb, A. Hassan
Journal: PLOS ONE
Volume/Issue: 18(5), e0281523
Year: 2023
Citations: 10
Summary: Examines how investor sentiment impacts both current (contemporaneous) and future equity returns in emerging markets, using empirical models.

2. Impact of Investor Sentiment on Contemporaneous and Future Equity Returns in Emerging Markets

Authors: R. Andleeb, A. Hassan
Journal: SAGE Open
Volume/Issue: 13(3), Article 21582440231193568
Year: 2023
Citations: 6
Summary: Similar theme as paper #1; provides additional or complementary analysis of sentiment-driven return predictability in emerging markets.

3. Nonlinear Relationship Between Investor Sentiment and Conditional Volatility in Emerging Equity Markets

Authors: R. Andleeb, A. Hassan
Journal: Asia-Pacific Financial Markets
Pages: 1–19
Year: 2024
Citations: 3
Summary: Investigates nonlinear effects of investor sentiment on volatility, suggesting a more complex dynamic beyond linear relationships.

4. Investor Sentiment Dynamics and Returns in Emerging Equity Markets

Author: R. Andleeb
Type: Ph.D. Thesis
Year: 2024
Citations: 2
Summary: Comprehensive doctoral research on the role and mechanisms of investor sentiment in shaping equity returns in emerging markets.

5. Behavioral Biases and Fintech Adoption: Investigating the Role of Financial Literacy

Authors: R. Aftab, A. Fazal, R. Andleeb
Journal: Acta Psychologica
Volume: 257, Article 105065
Year: 2025
Citations: 1
Summary: Explores how behavioral biases influence FinTech adoption, with financial literacy as a moderating factor.

6. Beyond Financial Metrics: A Balanced Scorecard Approach to Measure Technology Business Incubation Performance

Authors: A. Naeem, A. Masood, R. Andleeb, M.A. Mughal, S. Husain, Faizan Ul Haq
Journal: GRADIVA
Volume/Issue: 64(06), pp. 35–53
Year: 2025
Summary: Proposes a comprehensive evaluation framework using the Balanced Scorecard for assessing tech business incubation performance.

Conclusion

Dr. Rameeza Andleeb is highly deserving of a Best Researcher Award. Her early yet impactful academic journey, grounded in both innovation and scholarly excellence, showcases a researcher with not only technical competence but also a vision for transforming how finance is studied and applied in the digital era. Her dedication to interdisciplinary and applied research sets her apart as an emerging leader in her field.

Svetlana Ilić | Synthesis | Best Researcher Award

Posted on 09/07/202509/07/2025 by The Scientist

Dr. Svetlana Ilić | Synthesis | Best Researcher Award

Senior Research Associate at Vinča Institute of Nuclear Sciences, University of Belgrade, National Institute of the Republic of Serbia, Serbia.

Dr. Svetlana Ilić 🇷🇸 is a Senior Research Associate at the Vinča Institute of Nuclear Sciences, University of Belgrade. Born in Belgrade in 1981, she is a passionate and persistent researcher known for her expertise in ceramics and nanomaterials 🔬. Over the past 14+ years, Dr. Ilić has made significant contributions to sustainable materials research, focusing on mullite ceramics, porous structures, and environmental applications 🌱. She actively collaborates in European research networks and has authored numerous high-impact publications 🧪. Beyond her technical skills, she is a strong team player, quick learner, and dedicated scientist who continually seeks to innovate through natural and recycled resources 🌍. Dr. Ilić is also engaged in editorial roles and peer-reviewing for top international journals 📚. Her work is an excellent blend of academic excellence, environmental consciousness, and applied science.

Professional Profile